[Direct thrombin inhibition in interventional cardiology. The ACUITY trial].
The direct thrombin inhibitor bivalirudin was tested in the ACUITY Trial 13 819 patients with acute non-ST-segment elevation coronary syndrome in a prospective and randomized design. Three therapeutic regimens were compared in the context of an early invasive strategy: heparin plus glycoprotein IIb/IIIa inhibitor (GPI), bivalirudin plus GPI, or bivalirudin alone. Concerning the rate of ischaemic events bivalirudin alone was comparable to heparin plus GPI at a significantly lower rate of bleeding complications.
Heinze
H
H
Vivantes Klinikum Neukölln, Kardiologie und konservative Intensivmedizin, Rudower Strasse 48, 12351 Berlin.
Darius
H
H
D054058:Acute Coronary Syndrome / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000991:Antithrombins / Q000627:therapeutic use*; D017023:Coronary Angiography; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018579:Patient Selection; D013917:Thrombin / Q000037:antagonists & inhibitors*
D000991:Antithrombins; D013917:Thrombin